⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of NervGen Pharma Corp. and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
NervGen Pharma Corp.
↗Vancouver, Canada
NervGen Pharma is a clinical-stage biopharmaceutical company focused on developing first-in-class neuroreparative therapeutics. The company's mission is to enable the nervous system to repair itself, specifically targeting conditions such as spinal cord injury (SCI), multiple sclerosis, and other neurotraumatic or neurologic conditions.
Its lead therapeutic candidate, NVG-291, is a peptide designed to target the inhibitory CSPG-PTPσ pathway, which prevents nerve regeneration. The company is actively advancing its pipeline and recently transitioned to a NASDAQ listing, reflecting its growth and late-stage clinical development efforts.
CLASSIFICATION
SIZE & FINANCIALS
Employees:1-50
Founded:2017
Ownership:public
Status:operating
FUNDING
Stage:Public
STOCK
Exchange:NASDAQ
Ticker:NGEN
PIPELINE
Stage:Phase 3
Lead Drug Stage:Phase 3
Modalities:Peptide, Biologic
Active Trials:1
Trial Phases:Phase 3: 1
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Key Partnerships:Imeka Solutions Inc. (Neuroimaging technology for clinical trials)
COMPETITION
Position:Emerging
LEADERSHIP
Key Executives:
Adam Rogers - President & CEO
Keith Vendola - CFO
Shamim Ruff - Chief Regulatory Affairs Officer
Scientific Founders:Dr. Jerry Silver
Board Members:Harold Punnett, Brian Bayley, Randall Kaye, Neil Klompas, Krista McKerracher, John Ruffolo, Craig Thompson
LINKS
Website:nervgen.com
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with NervGen Pharma Corp.. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.